Abstract. Despite tremendous effort and progress in the diagnostics of pancreatic cancer with respect to imaging techniques and molecular genetics, only very few patients can be cured by surgery leading to a 5-year survival rate of only 3%. Especially the lack of chemotherapeutical options in this entity requires a better understanding of the molecular mechanisms leading to pancreatic carcinoma growth and progression in order to develop novel treatment regimens. To identify signaling pathways that are critical for this tumor entity, we compared six well-established pancreatic cancer cell lines (Capan-1, Capan-2, HUP-T3, HUP-T4, KCL-MOH, PaTu-8903) with colon cancer cell lines and tumor cell lines of non-epithelial origin by expression profiling. For this purpose we employed Human Genome Focus Arrays representing about 8500 well annotated human genes. We identified 353 genes with significantly high expression in the group of pancreatic carcinomas. Based on Gene Ontology annotations these genes are especially involved in Rho protein signal transduction, proteasome activator activity, cell motility, apoptotic program, and cell-cell adhesion processes indicating these pathways to be interesting candidates for the design of targeted therapies. Most pancreatic carcinomas are characterized by mutations in the TP53 and the KRAS genes and the absence of microsatellite instability, which could also be confirmed for our panel of pancreatic carcinoma cell lines. Looking for individual differences within this group that may be responsible for more or less aggressive behavior, we identified genomic amplifications at the 8q22.1 and the 8q24.22 loci to be associated with enhanced gene transcription. Because we have previously shown that gains of genomic material from the long arm of chromosome 8 have an adverse effect on the outcome of pancreatic carcinoma patients, we conclude that functional analysis of amplified genes at 8q22 and/or 8q24 may lead to an improved understanding of pancreatic carcinoma progression.
Introduction
Pancreatic cancer is one of the most malignant diseases in the world. Unfortunately, only very few patients suffering from pancreatic cancer can be cured by surgery leading to a 5-year survival rate of only 3% (1) . The poor prognosis is due to the difficulty of diagnosis at an early stage for surgery with curative intention and the lack of chemotherapeutical options in this entity. In order to save patients with pancreatic cancer it is necessary to develop novel methods for diagnosis and treatment. A better understanding of the molecular mechanisms involved in pancreatic carcinogenesis remains a major objective since it may help in designing strategies for earlier diagnosis and better treatment (2, 3) .
Genetic changes leading to tumor progression affect cell cycle regulation, apoptosis, signal transduction, cell adhesions cytoskeletal structure, angiogenesis and genomic stability (4) . However, the processes of identifying the affected genes and of determining their roles in carcinogenesis, progression and response to therapy have been challenging. One important approach to detect cancer related genes is the identification of differentially expressed transcripts either between tumors and their respective normal tissues or among various tumor entities (4) . The development of DNA microarray technology has provided the opportunity to simultaneously evaluate the expression patterns of thousands of genes. The generation and comparison of gene expression profiles allow the identification of multi-gene expression patterns that provide an insightful view into regulatory mechanisms, cellular functions and biochemical pathways. To identify signaling pathways that are critical for this tumor entity, we compared the transcriptional profile of six well-established pancreatic cancer cell lines to colon cancer cell lines as well as tumor cell lines of non-epithelial origin.
Materials and methods

Cell lines.
Overall our experiments included 10 cell lines derived from six pancreatic carcinomas, two colorectal carcinomas, as well as two neuroblastomas (Table I ). All cell lines were maintained using standard procedures as previously described (4) . Absence of mycoplasma contamination was determined by the PCR-based VenorGeM Mycoplasma PCR detection kit (Minerva Biolabs GmbH, Berlin, Germany) according to the manufacturer's protocols.
Microarray hybridization and data analysis. Human Genome Focus Arrays (Affymetrix, Santa Clara, CA) were employed to analyze the expression of about 8500 human genes. The preparation and processing of labeled and fragmented cRNA targets is detailed elsewhere (5) . Briefly, total-RNAs were prepared from cells using TRIzol reagent (Life Technologies, Germany). A T7-(dT)24 primer (Eurogentec, Belgium) was used to synthesize double-stranded, T7-tailed cDNAs directly from 5 μg of each total-RNA using Superscript™ Choice System for cDNA synthesis (Life Technologies). Biotinylated cRNAs were in vitro transcribed from each cDNA (biotinylated-11-CTP and -16-UTP; BioArray™ HighYield™ RNA transcript labeling kit, Enzo Diagnostics, Farmingdale, NY) and fragmented. Cocktails including labeled and fragmented cRNAs and hybridization controls were hybridized on the arrays for 16 h at 45˚C (GeneChip hybridization oven). The microarrays were washed as required and stained using 10 μg/ml streptavidin-phycoerythrin (Molecular Probes, OR). Microarray images were obtained with a GeneArray™ scanner (Hewlett Packard, Palo Alto, CA). GeneChip microarray analysis experiment reports were inspected (background, noise, scaling factor, fraction of 'present calls', presence of hybridization controls) to assure equal experiment quality. Overall quality was good and no outlier experiments had to be excluded.
In addition, GeneData refiner (GeneData, Basel, Switzerland) was used to quality check and import experiments with detection and masking of outliers and array defects, to assess GAPDH and ß-actin housekeeping controls using 3'/5' ratios, and to condense chip intensities to signal values using the 'affymetrix statistical (MAS5)' method. GeneData Analyst (version EPro 1.0.17) normalized the expression values to an arithmetic mean of 200 (as this minimally shifts the signal ranges of all experiments). To identify the differentially expressed genes we computed two-sample, two sided t-tests between tumor subgroups. Genes with a p-value <0.05 were considered candidate genes. For the visualization of experiment structure, clustering was done using the euclidean distance measure and the 'complete linkage' methods. Gene descriptions are affymetrix gene descriptions and gene ontology identifiers are part of the GeneData Analyst results sheet. Fisher's exact test was used to decide whether gene ontology identifiers show a tendency of over-or under-representation in a candidate gene list compared with all measured probe sets.
To screen for gain of genomic material leading to an aberrant transcription pattern we used the 'amplicon identification' module of the GeneData Expressionist Software, which seeks for contiguous regions (2-100 consecutive loci) on a chromosome where genes show consistent and significant (based on t-test statistics) deviation from the mean of all the pancreatic tumor samples.
Screening for TP53 and KRAS gene mutation. Cycle sequencing analysis of TP53 gene exons 5-8 was performed with the BigDye Terminator system (PE-Biosystems, Weiterstadt, Germany) using primers as described elsewhere (6) . Primers for KRAS gene exon 1 analysis were KRAS_fwd 5'-AGGCCTGCTGAAAATGACTGAA-3' and KRAS_rev 5'-AAAGAATGGTCCTGCACCAG-3'. The reaction products were analyzed on an ABI PRISM 3700 sequencer (PEBiosystems) using amplification primers for sequencing.
Analysis of microsatellite instability (MSI).
In accordance with the recommendations by the National Cancer Institute (NCI), five microsatellite loci were used in all tumor cell lines to detect MSI: two loci with mononucleotide sequences (BAT25, BAT26) and three loci with CA dinucleotide repeats (D2S123, D5S346, D17S250). PCR and fragment length analysis was performed as described elsewhere (7) . Due to the lack of corresponding tumor-free tissue, the MSI status of the cell lines was interpreted based on the quasi-monomorphic mononucleotide markers BAT25 and BAT26.
Amplicon identification by multiplex PCR. To monitor gains of genetic material at chromosome 8q-loci showing significantly enhanced gene expression (see above), we developed a multipex PCR assay, which allows the simultaneous investi- Table I . Characterization of tumor cell lines. 
NB, neuroblastoma; CRC, colorectal carcinoma; PC, pancreatic carcinoma; ATCC, American Type Culture Collection; DSMZ, German resource center for biological material.
gation of six loci. The genes represented in this assay, their chromosomal localization, primer sequences, and the expected product size are listed in Table II . Amplification was performed in a total volume of 20 μl containing 20 ng genomic DNA, 0.2 mM dNTP, primers as specified in Table II , and 0.5 U Taq polymerase (HotStar Taq, Qiagen, Hilden, Germany) together with the corresponding buffer. PCR products were separated on an ABI PRISM™ 310 Genetic Analyzer and quantified using the GeneScan™ Analysis Software (PE Applied Biosystems). The algorithm for peak area interpretation was adapted from a screening approach for gains of chromosome 1q as described by Corson et al (8) . For normalization of peaks within each sample, the relative signal value was calculated as the ratio of the peak area divided by the mean peak area of the six different loci. Using these normalized data, again a mean value (mean_locus) was calculated for each gene locus. We considered gene loci to be amplified if their relative signal values were greater than mean_locus + 1 SD.
Results
Comparison of pancreatic carcinoma versus other tumor entities.
In a first approach the expression profile data of the six pancreatic carcinoma samples were compared to other tumor entities to define signaling pathways typically involved in the genesis of pancreatic carcinoma. This comparison included other adenocarcinomas (of the colorectum) as well as tumors of neuroectodermal origin (neuroblastomas).
Unsupervised cluster analysis (based on all the 8793 probe sets) clearly revealed the separation of the three different tumor groups (Fig. 1) . As expected the tumors were first divided into the two groups comprising the two neuroectodermal and the eight epithelial samples, respectively. The latter group harboring the adenocarcinomas is then further dichotomized according to the tissue of origin.
To identify the signaling pathways that are responsible for this clear clustering we determined the significantly differentially expressed genes by t-test statistics. Excluding all probe sets which are called 'absent' (MAS 5.0, Affymetrix) in all the ten samples we observed 765 probe sets to have significantly (p<0.05) low expression in the pancreatic cell lines and 353 probe sets to have significantly high expression (the top 85 genes for p<0.005 are listed in Table IV , complete data set available at http://home.rz.uni-duesseldorf.de/~k-sch001/ download/Domagk_Schaefer_high_in_pancreatic_ carcinoma. Based on the list of significantly highly-expressed genes in combination with the corresponding GeneOntology annotations we found that biological processes like Rho protein signal transduction (GO:0007266, GO:0005094), proteasome activator activity (GO:0008537, GO:0008538), cell motility (GO:0006928, GO:0005200, GO:0008243), apoptotic program Table II . Primers for chromosome 8q multiplex PCR. Table IV . List of genes significantly (p<0.005) highly expressed in pancreatic cell lines. Table IV . Continued.
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malignant cell transformation we determined the mutational status of the tumor suppressor gene TP53 and the KRAS oncogene and the status of microsatellite instability.
All the six pancreatic adenocarcinoma samples could be shown to harbor a missense mutation within the KRAS gene at codon 12 (with or without loss of wild-type allele) (Table III) .
Regarding the status of TP53 gene mutation only the cell line CAPAN-2 did not show any missense mutation in the core region of this important tumor suppressor gene (Table III) . None of the cell lines was characterized by microsatellite instability (data not shown).
Differences within the group of pancreatic carcinoma. In a former study on primary pancreatic carcinoma samples from 33 patients we were able to define amplifications on the long arm of chromosome 8 to be significantly associated with reduced overall survival (9) . We therefore used our in vitro model of six carcinoma cell lines to screen for aberrant transcription patterns as a consequence of gain of genomic material. For this purpose we used the 'amplicon identification' module of the Expressionist Software (GeneData), which seeks for contiguous regions on a chromosome where genes show consistent and significant deviation from the mean of all the pancreatic tumor samples.
In the six cell lines, the software identified 13 chromosome 8 loci showing elevated gene activity. On the other hand, four loci were characterized by significantly reduced gene activity (Fig. 2) . The regions of differential gene activity varied dramatically in size ranging from 0.03 to 25.8 Mb (median 6.1 Mb) for the highly-expressed genes and from 0.06 to 30.2 Mb (median 11.6 Mb) for the lowly-expressed genes.
Overall six loci were identified showing aberrant gene activity in more than one cell line probably as a result of a non- Table V . Biological processes significantly over-represented in all the genes highly expressed in pancreatic carcinoma cell lines according to GeneOntology annotation. 
-------------------------------------------------Property name P-value -------------------------------------------------
We developed a multiplex PCR assay to investigate whether these loci of enhanced gene activity are over-represented on the genomic level. Using amplicons of the genes CEBPD (8q11.21), MOS (8q12.1), SGKL (8q13.1), PPM2C (8q22.1), NDRG1 (8q24.22) and LY6D (8q24-qter) we identified two loci (8q22.1 and 8q24.22) which were represented by enhanced PCR-signals in the cell line HuPT3 (Fig. 3) . For both of these loci the 'amplicon identification' module of the Expressionist Software had predicted these regions to be amplified in this cell line. The locus at 8q22.1 harbors the region from PPM2C (protein phosphatase 2C) to TAF2 (TAF2 RNA polymerase II) and consists of 32 quantified genes (mean expression fold change: 1.39, compared to the other 5 pancreatic cell lines). The locus 8q24.22 comprises the genes TRIB1, MYC, LRRC6, NDRG1, KHDRBS3 and PTK2 (mean fold change: 2.49). For the remaining four candidate loci, no gain of genetic material could be detected by the multiplex assay.
Discussion
Despite tremendous effort and progress in the diagnostics of pancreatic cancer with respect to imaging techniques and molecular genetics, pancreatic cancer is still considered as a malignant entity with a dismal prognosis (1, (10) (11) (12) (13) (14) . Ductal adenocarcinoma and its variants (e.g., mucinous non-cystic carcinoma and signet cell carcinoma) are the most common neoplasms in the pancreas, representing 85-90% of all pancreatic neoplasms. In western civilization, the annual age adjusted incidence rates range from 3.1 (Herault, France) to 20.8 (Central Louisiana, USA) per 100,000 males and from 2.0 (Herault) to 11.0 (San Francisco, USA) per 100,000 females (13) . Approximately, 80% of the cases manifest clinically in patients between 60 and 80 years whereas young patients below the age of 40 years suffering from pancreatic cancer are extremely rare (12) . Caucasians have a distinctly lower rate than African Americans (11) . The development of pancreatic cancer is strongly related to cigarette smoking, which carries a 2-to 3-fold relative risk that increases with the number of pack-years of smoking. Chronic pancreatitis, past gastric surgery, occupational exposure to chemicals, radiation exposure and diabetes mellitus have also been associated with the development of pancreatic cancer; furthermore, a markedly increased risk has been observed in hereditary pancreatitis (10) . Ductal adenocarcinoma is fatal in most cases; the mean survival time of the untreated patient is 3 months, while the mean survival after radical resection varies from 10 to 20 months (15) (16) (17) . The overall 5-year survival rate of patients treated by resection is 3-4%, although in selected and stage- stratified series higher survival figures have been reported (18) . Response to chemotherapy may be seen in a small proportion of patients whereas radiotherapy alone is largely ineffective (19) (20) (21) . Unresected carcinomas, due for example to vascular invasiveness or lymph node metastases, may be treated by palliative bypass surgery. Patients with no residual tumor following resection (R0) have the most favorable prognosis of all patients undergoing surgical resection; this implies that local spread of peripancreatic tissues is of utmost importance in terms of prognosis (18, 22, 23) . Genetic alterations in pancreatic carcinomas include losses and gains of genetic material as well as generalized chromosome instability. The most frequent gains include those of chromosomes 12 and 7 (24) (25) (26) . Recurrent losses of genetic material at specific loci in a carcinoma suggest that these loci harbor tumor suppressor genes which are inactivated in the carcinoma. In pancreatic cancer, the gene coding for p16 on 9p, the TP53 gene on 17p, and the DPC4 gene on 18q are all frequently inactivated (27) . Several oncogenes have been shown to be activated in ductal adenocarcinomas of the pancreas. These include the KRAS gene on chromosome 12p, which is activated by point mutations in over 90% of the carcinomas (14) . DNA mismatch repair genes, such as MLH1 and MSH2, can also play a role (14) . However, microsatellite instability resulting from inactivation of both alleles of a DNA mismatch repair gene has been identified in only 4% of pancreatic cancer (28) .
Since these genetic changes are not unique to pancreatic carcinoma we sought to identify pathways that may be specific for the characteristic biology of these tumor cells. Among the 27 most significant (p<0.01) signaling pathways as defined by Gene Ontology (GO)-terms, which describe the biological behavior of our six pancreatic carcinoma cell lines (compared to the other tumor cell lines), we found the terms 'GO:0005911 intercellular junction, p=0.00214' and 'GO:0016337 cell-cell adhesion, p=0.00703' indicating an outstanding impact of cell adhesion processes to pancreatic tumor development and progression. This result was based on the differential expression pattern of 21 genes involved in these pathways including ß-catenin (CTNNB1), tight junction protein 2 (TJP2), neuronal cell adhesion molecule (NRCAM), and dysadherin (FXYD5), which are all known to play essential roles in pancreatic tumor oncogenesis (29) (30) (31) (32) (33) . Significantly, in a recent meta-analysis of four different expression profiling studies which all included primary tumor tissue and normal pancreatic specimens (34), cell-cell adhesion processes were also identified to be of prime importance for the malignant transformation of pancreatic carcinoma. These findings underline, that genes involved in this pathway are interesting new targets for the development of alternative treatment strategies of pancreatic carcinoma.
In a recent CGH study comprising 33 patients with resectable pancreatic carcinoma (9) we have observed gains of the long arm of chromosome 8 to represent an independent predictor of reduced survival [hazard ratio 2.415, 95% confidence interval (2.02-2.81)]. Since chromosome 8q was also shown in other carcinomas to be at least associated with advanced disease stage [33 prostate carcinomas (35) , 76 breast cancer patients (36) , and 50 colorectal carcinomas (37)] we sought to identify chromosomal regions on 8q with increased copy numbers which, in turn, lead to an aberrant gene transcription pattern.
For this approach we first defined a set of candidate regions based on the differential gene expression pattern in the pancreatic carcinoma cell lines and, in a second step, validated these regions by multiplex PCR assays on genomic DNA.
Among the set of candidates we could prove two 8q regions (8q21.3-q24.12 and 8q24.13-qter) in the cell line HuPT3 to be characterized both by an elevated gene activity and by a gain of genomic material. In a recent extensive array-based CGH approach (38) , at least the 8q24 region of HuPT3, but not of Capan-2, HuPT4 or PaTu8902, was also shown to be amplified, underlining the feasibility of our straightforward multiplex PCR assay. These regions contain EBAG9 (estrogen receptor binding site associated, antigen, 9; synonymous with RCAS1) which is involved in the immune escape mechanism of cancer cells and the MYC gene which is critical for cell proliferation. In previous studies high expression of EBAG9 has been shown to be an independent adverse marker of survival in pancreatic carcinoma (39) , while the expression of MYC could not be shown to have implications on patient survival (30) . It will be interesting to evaluate if the overexpression of EBAG9 is correlated with gain of chromosome 8q in primary tumor specimens, and to elucidate the prognostic impact of these two events in the same collective of patients.
